产品
编 号：F151075
分子式：C21H22N2O6S
分子量：430.47
分子式：C21H22N2O6S
分子量：430.47
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1401089-31-3
产品详情
生物活性：
PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues. PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
体内研究：
PACMA 31 (20 -200 mg/kg；腹腔注射；每日一次，持续 62 天) 抑制人卵巢癌小鼠异种移植物中的肿瘤生长。Animal Model:Athymic mice (bearing OVCAR-8 cells)
Dosage:20-200 mg/kg
Administration:I.p., per day for the first 3 wk with 5-d on and 2-d off treatment cycles, and dose was escalated to 40 mg/kg per day for the next 7 d; p.o., the initial dose of 20 mg/kg per day was gradually increased by 20 mg/kg per day with each dose for 3 d before it was orally dosed at 200 mg/kg per day for an additional 32 d, increasing the dose from 20 to 200 mg/kg
Result:Compared with the control group, i.p. or per os administration of PACMA 31 significantly inhibited tumor growth by 85% and 65% at day 62, respectively.
体外研究：
PACMA 31 (0-10 μM；24 小时) 以剂量依赖性方式显著抑制 OVCAR-8 细胞的集落形成。
PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues. PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
体内研究：
PACMA 31 (20 -200 mg/kg；腹腔注射；每日一次，持续 62 天) 抑制人卵巢癌小鼠异种移植物中的肿瘤生长。Animal Model:Athymic mice (bearing OVCAR-8 cells)
Dosage:20-200 mg/kg
Administration:I.p., per day for the first 3 wk with 5-d on and 2-d off treatment cycles, and dose was escalated to 40 mg/kg per day for the next 7 d; p.o., the initial dose of 20 mg/kg per day was gradually increased by 20 mg/kg per day with each dose for 3 d before it was orally dosed at 200 mg/kg per day for an additional 32 d, increasing the dose from 20 to 200 mg/kg
Result:Compared with the control group, i.p. or per os administration of PACMA 31 significantly inhibited tumor growth by 85% and 65% at day 62, respectively.
体外研究：
PACMA 31 (0-10 μM；24 小时) 以剂量依赖性方式显著抑制 OVCAR-8 细胞的集落形成。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备